Leonora R. Slatnick
No Rating Available
(Learn About Our Rating System)

Leonora R. Slatnick, MD, MSCS

Languages spoken: English, Spanish

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City
801-587-4745
Directions

University Pediatric Clinic

University Pediatric Clinic
Salt Lake City
801-581-2205
Directions

  • Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School.

    She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado.

    Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, Children's Oncology Group, The National Comprehensive Cancer Network (NCCN) Neuroblastoma Committee, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience.

    Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
    National Board of Medical Examiners

  • Dr. Slatnick is currently an assistant professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. She is a member of the Solid Tumor team at the University of Utah and Primary Children’s Hospital. She received her medical degree from the University of Texas Southwestern Medical School.

    She completed her pediatric residency in Pediatrics at the University of Colorado School of Medicine. She also completed her fellowship in Pediatric Hematology-Oncology and MSCS degree in Clinical Sciences at the University of Colorado.

    Dr. Slatnick is board-certified by the American Board of Pediatrics and National Board of Medical Examiners. She is a member of many professional societies, including The American Academy of Pediatrics, Children's Oncology Group, The National Comprehensive Cancer Network (NCCN) Neuroblastoma Committee, The American Society of Clinical Oncology, The American Society of Hematology, and the Children’s Oncology Group. She has over 10 years of research experience.

    Dr. Slatnick’s clinical interests include all solid tumors with a specific interest in neuroblastoma therapy. Her primary research focuses on supportive care practices in immunocompromised patients, with a particular interest in infectious complications and antimicrobial management in the oncology patient population.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Assistant Professor (Clinical)
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)
    National Board of Medical Examiners

    Education history

    Fellowship Pediatric Hematology-Oncology - University of Colorado School of Medicine Fellow
    Graduate Training Clinical Sciences - University of Colorado Anschutz Medical Campus M.S.
    Residency Pediatrics - University of Colorado School of Medicine Resident
    Internship Pediatrics - University of Colorado School of Medicine Intern
    Professional Medical Medicine - University of Texas Southwestern Medical School M.D.
    Other Training Study Abroad Spanish Curriculum - Universidad de Salamanca
    Undergraduate Major: Cell Biology and Neuroscience; Minors: Spanish Language, Psychology - Rutgers University B.S.

    Selected Publications

    Journal Article

    1. Slatnick LR, Hoogstra D, Fisher BT, Wolf J, Orgel E, Nessle CN, Patel PA, Miller TP, Wilkes J, Dupuis LL, Goode E, Jackson K, Willis DN, Elgarten C, Aftandilian C, Thompson J, Alexander S, Beauchemin MP, Belsky JA, Hess J, Prudowsky ZD, Guinipero T, Rossoff J, Demedis J, Walsh AM, Richards R, Choi DK, Dvorak CC, Esbenshade AJ (2025). Prevention and Management of Infectious Complications in Pediatric Patients With Cancer: A Survey Assessment of Current Practices Across Children's Oncology Group Institutions. Pediatr Blood Cancer, e31532. (Read full article)
    2. Zhao Z, Patel PA, Slatnick L, Sitthi-Amorn A, Bielamowicz KJ, Nunez FA, Walsh AM, Hess J, Rossoff J, Elgarten C, Myers R, Saab R, Basbous M, Mccormick M, Aftandilian C, Richards R, Nessle CN, Tribble AC, Sheth Bhutada JK, Coven SL, Runco D, Wilkes J, Gurunathan A, Guinipero T, Belsky JA, Lee K, Wong V, Malhotra M, Armstrong A, Jerkins LP, Cross SJ, Fisher L, Stein MT, Wu NL, Yi T, Orgel E, Haeusler GM, Wolf J, Demedis JM, Miller TP, Esbenshade AJ (2023). Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer. J Clin Oncol, 42(7), 832-841. (Read full article)
    3. Slatnick LR, Cost C, Garrington T, Donaldson N, Macy ME (2024). Central Nervous System Metastases in Pediatric Patients With Ewing Sarcoma. J Pediatr Hematol Oncol, 46(2), e180-e183. (Read full article)
    4. De Castro GC, Slatnick LR, Shannon M, Zhao Z, Jackson K, Smith CM, Whitehurst D, Elliott C, Clark CC, Scott HF, Friedman DL, Demedis J, Esbenshade AJ (2023). Impact of Time-to-Antibiotic Delivery in Pediatric Patients With Cancer Presenting With Febrile Neutropenia. JCO Oncol Pract, 20(2), 228-238. (Read full article)
    5. Slatnick LR, Miller K, Scott HF, Loi M, Esbenshade AJ, Franklin A, Lee-Sherick AB (2022). Serum lactate is associated with increased illness severity in immunocompromised pediatric hematology oncology patients presenting to the emergency department with fever. Front Oncol, 12, 990279. (Read full article)
    6. Slatnick LR, Jimeno A, Gore L, Macy ME (2021). Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc), 57(11), 677-688. (Read full article)
    7. Slatnick LR, Thornhill D, Deakyne Davies SJ, Ford JB, Scott HF, Manco-Johnson MJ, Warren BB (2020). Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. J Pediatr, 225, 198-206.e2. (Read full article)

    Letter

    1. Slatnick LR, Angione K, Hartman L (2022). Precursor B-cell acute lymphoblastic leukemia in a pediatric patient with Bainbridge-Ropers syndrome. [Letter to the editor]. Pediatr Blood Cancer, 70(1), e29873. (Read full article)

    Other

    1. Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai AV, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L (2024). Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (22(6), pp. 413-433). United States. (Read full article)